The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine

Simple item page
dc.contributor.authorCameron, Michael Patrick
dc.contributor.authorNewman, Peter A.
dc.contributor.authorRoungprakhon, Surachet
dc.contributor.authorScarpa, Riccardo
dc.coverage.spatialNetherlandsen_NZ
dc.date.accessioned2013-09-27T04:43:28Z
dc.date.available2013-09-27T04:43:28Z
dc.date.copyright2013-08
dc.date.issued2013
dc.description.abstractThis paper estimates the marginal willingness-to-pay for attributes of a hypothetical HIV vaccine using discrete choice modeling. We use primary data from 326 respondents from Bangkok and Chiang Mai, Thailand, in 2008–2009, selected using purposive, venue-based sampling across two strata. Participants completed a structured questionnaire and full rank discrete choice modeling task administered using computer-assisted personal interviewing. The choice experiment was used to rank eight hypothetical HIV vaccine scenarios, with each scenario comprising seven attributes (including cost) each of which had two levels. The data were analyzed in two alternative specifications: (1) best-worst; and (2) full-rank, using logit likelihood functions estimated with custom routines in Gauss matrix programming language. In the full-rank specification, all vaccine attributes are significant predictors of probability of vaccine choice. The biomedical attributes of the hypothetical HIV vaccine (efficacy, absence of VISP, absence of side effects, and duration of effect) are the most important attributes for HIV vaccine choice. On average respondents are more than twice as likely to accept a vaccine with 99% efficacy, than a vaccine with 50% efficacy. This translates to a willingness to pay US$383 more for a high efficacy vaccine compared with the low efficacy vaccine. Knowledge of the relative importance of determinants of HIV vaccine acceptability is important to ensure the success of future vaccination programs. Future acceptability studies of hypothetical HIV vaccines should use more finely grained biomedical attributes, and could also improve the external validity of results by including more levels of the cost attribute.en_NZ
dc.identifier.citationCameron, M. P., Newman, P. A., Roungprakhon, S., & Scarpa, R. (2013). The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine, 31(36), 3712-3717.en_NZ
dc.identifier.doi10.1016/j.vaccine.2013.05.089en_NZ
dc.identifier.urihttps://hdl.handle.net/10289/8033
dc.language.isoenen_NZ
dc.publisherElsevieren_NZ
dc.relation.isPartOfVaccineen_NZ
dc.relation.ispartofVaccine
dc.relation.urihttp://www.sciencedirect.com/science/article/pii/S0264410X13007068en_NZ
dc.subjectHIV vaccineen_NZ
dc.subjectwillingness-to-payen_NZ
dc.subjectconjoint analysisen_NZ
dc.subjectdiscrete choiceen_NZ
dc.subjectThailanden_NZ
dc.titleThe marginal willingness-to-pay for attributes of a hypothetical HIV vaccineen_NZ
dc.typeJournal Articleen_NZ
pubs.begin-page3712en_NZ
pubs.elements-id38518
pubs.end-page3717en_NZ
pubs.issue36en_NZ
pubs.volume31en_NZ
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Name: license.txt
Size: 1.71 KB
Kind: License
Collections
Management Papers